This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Summit Therapeutics Stock Price Rose 6% on Friday
by Zacks Equity Research
SMMT stock rose after analysts at Jefferies initiated coverage on it, citing optimism about the company's lead pipeline drug.
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYC
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
by Zacks Equity Research
MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster drug, Keytruda, in a lung cancer study.
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
by Zacks Equity Research
BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales
by Zacks Equity Research
SMMT's third-quarter earnings miss estimates. Management also provides updates on the company's pipeline.
Summit Therapeutics Stock: Sell or Hold Before Q3 Earnings?
by Zacks Equity Research
Devoid of any marketed drug in its portfolio, investors will likely focus on SMMT's pipeline updates when it reports third-quarter results this month.
Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold?
by Zacks Equity Research
The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the next standard of care in the NSCLC space.
Instil Bio Stock Skyrockets 641% in One Week: Here's Why
by Zacks Equity Research
A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.
Biotech Stock Roundup: TERN, SMMT Stocks Surge on Study Data, GSK's Vaccine Study Fails & More
by Zacks Equity Research
Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.
Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda
by Zacks Equity Research
Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
by Zacks Equity Research
Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.
Company News for Sep 10, 2024
by Zacks Equity Research
Companies in The News Are: BA,SMMT,CRM,META
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FYC
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
by Zacks Equity Research
Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.
Summit Therapeutics PLC (SMMT) Moves 17.4% Higher: Will This Strength Last?
by Zacks Equity Research
Summit Therapeutics PLC (SMMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Summit Therapeutics (SMMT) Surges: Stock Moves 7.2% Higher
by Zacks Equity Research
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
New Strong Sell Stocks for October 30th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.75, marking a +1.08% move from the previous day.
Is Summit Therapeutics (SMMT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (SMMT) Outperforming Other Medical Stocks This Year?
Summit Therapeutics PLC (SMMT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Summit Therapeutics PLC (SMMT) closed at $4.20 in the latest trading session, marking a +1.94% move from the prior day.
Summit Therapeutics PLC (SMMT) Stock Moves -0.43%: What You Should Know
by Zacks Equity Research
In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.48, marking a -0.43% move from the previous day.
Will Ventilator Sales Drive Medtronic's (MDT) Q4 Earnings?
by Zacks Equity Research
Medtronic (MDT) might have registered lower demand for its emergency procedures in Q4 with patients trying to avoid any non-COVID-19 emergency treatment.
CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.